ANI Pharmaceuticals Chief Financial Officer Stephen Carey sold 3,313 shares of common stock on July 2, 2026, for a total transaction value of about $285,000. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted in March 2026, involving the exercise of 3,313 options at $49.51 per share and an immediate open-market sale at a weighted-average price of $86.00. The disposition represented just 2% of Carey's direct equity holdings, leaving him with 177,543 directly held shares valued at approximately $15.27 million based on the market close. At the time of the transaction, ANI Pharmaceuticals had a market capitalization of $2.0 billion and the stock had delivered a one-year total return of 32%.
ANI Pharmaceuticals IncCFO sold shares, which may signal insider bearishness despite being pre-planned.